Nanjing Hanxin Pharmaceutical Technology

Executive Summary

Nanjing Hanxin Pharmaceutical Technology is a private, clinical-stage biopharmaceutical company based in Nanjing, China, focused on discovering and developing innovative small-molecule therapies for oncology and immunology. Founded in 2016, the company leverages proprietary drug discovery platforms to build a pipeline of targeted therapies and immunomodulators. Hanxin has advanced multiple candidates into Phase 1 clinical trials, aiming to address high unmet medical needs in cancer and immune-related diseases. With a lean R&D team of 50–200 employees and a stage-1 profile, the company represents an early-stage investment opportunity in China's rapidly growing biotech sector. While no specific pipeline assets have been disclosed in public databases, the company's strategic focus on novel mechanisms of action and its presence in Nanjing's biotech hub provide a foundation for potential value creation through clinical data readouts and partnership opportunities.

Upcoming Catalysts (preview)

• TBDPhase 1 dose-escalation data for lead oncology candidate60% success
• Q3 2026IND filing for next-generation immunomodulator75% success
• 2027Potential strategic partnership or licensing deal for preclinical asset40% success